> A new study published in Nature Biotechnology confirms that Sirna Therapeutics technology may well form the basis of a new class of drugs -- sending its stock up 50 percent. Story
> Citing conflicting trial data, the FDA has rejected Forest Laboratories' bid to market Namenda as a treatment for mild Alzheimer's. Report
> Shares of ImmunoGen were on the rise this morning after it announced a new licensing deal with Genentech for its cancer-fighting agents. Story
> GlaxoSmithKline, Europe's biggest drug maker, launched Phase III clinical trials of a treatment for AIDS made by Ono Pharmaceutical. The drug, called ONO-4128/873140, will be administered to HIV-positive patients who already have been treated with other AIDS drugs. Ono licenses the drug to GlaxoSmithKline, which is expanding its line-up of AIDS treatments. Story
> Adventrx's NNRTI drug shows in-vitro power against resistant HIV. Release
> Valeant Pharmaceuticals plans to start Phase III trials of Retigabine, its first-in-class epilepsy drug. Release
> Serologicials subsidiary Chemicon International has inked a deal to commercialize research products based on patented human embryonic stem (ES) cell technology developed by Wisconsin Alumni Research Foundation. Release
> 454 Life Sciences receives $11.5 million in milestone payments from Roche. Release
> ImClone profit climbs on sales of its Erbitux cancer drug. Story
And Finally... Mars chocolatiers are in talks with biotechs to develop medical applications for cocoa flavanols. Report